Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia

Daniela Montagna, Rita Maccario, Franco Locatelli, Enrica Montini, Sara Pagani, Federico Bonetti, Liane Daudt, Ilaria Turin, Daniela Lisini, Claudio Garavaglia, Paolo Dellabona, Giulia Casorati

Research output: Contribution to journalArticle

Abstract

Although the graft-versus-leukemia effect of allogeneic bone marrow transplantation (BMT) is of paramount importance in the maintenance of disease remission, the role played by the autologous T-cell response in antitumor immune surveillance is less defined. We evaluated the emergence of antileukemia cytotoxic T-lymphocyte precursors (CTLp's) and the correlation of this phenomenon with maintenance of hematologic remission in 16 children with acute myeloid leukemia (AML), treated with either chemotherapy alone (5 patients) or with autologous BMT (A-BMT, 11 patients). Antileukemia CTLp's were detectable in 8 patients in remission after induction chemotherapy; none of them subsequently had a relapse. Of the 8 patients who did not show detectable CTLp frequency while in remission after induction chemotherapy, 7 subsequently experienced leukemia relapse. In patients undergoing A-BMT, molecular fingerprinting of the TCR-Vβ repertoire, performed on antileukemia lines, demonstrated that selected antileukemia T-cell clonotypes, detectable in bone marrow before transplantation, survived ex vivo pharmacologic purging and were found in the recipient after A-BMT. These data provide evidence for an active role of autologous T cells in the maintenance of hematologic remission and also suggest that quantification of antileukemia CTLp frequency may be a useful tool to identify patients at high risk for relapse, thus potentially benefiting from an allogeneic antitumor effect.

Original languageEnglish
Pages (from-to)3843-3850
Number of pages8
JournalBlood
Volume108
Issue number12
DOIs
Publication statusPublished - Dec 1 2006

Fingerprint

T-cells
Bone Marrow Transplantation
Acute Myeloid Leukemia
Maintenance
Cytotoxic T-Lymphocytes
Bone
T-Lymphocytes
Chemotherapy
Remission Induction
Induction Chemotherapy
Recurrence
Leukemia
Transplantation (surgical)
Autologous Transplantation
Homologous Transplantation
Purging
Grafts
Transplants
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. / Montagna, Daniela; Maccario, Rita; Locatelli, Franco; Montini, Enrica; Pagani, Sara; Bonetti, Federico; Daudt, Liane; Turin, Ilaria; Lisini, Daniela; Garavaglia, Claudio; Dellabona, Paolo; Casorati, Giulia.

In: Blood, Vol. 108, No. 12, 01.12.2006, p. 3843-3850.

Research output: Contribution to journalArticle

@article{3a14bdbb2fbc4b619f1b1262a42cfa0d,
title = "Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia",
abstract = "Although the graft-versus-leukemia effect of allogeneic bone marrow transplantation (BMT) is of paramount importance in the maintenance of disease remission, the role played by the autologous T-cell response in antitumor immune surveillance is less defined. We evaluated the emergence of antileukemia cytotoxic T-lymphocyte precursors (CTLp's) and the correlation of this phenomenon with maintenance of hematologic remission in 16 children with acute myeloid leukemia (AML), treated with either chemotherapy alone (5 patients) or with autologous BMT (A-BMT, 11 patients). Antileukemia CTLp's were detectable in 8 patients in remission after induction chemotherapy; none of them subsequently had a relapse. Of the 8 patients who did not show detectable CTLp frequency while in remission after induction chemotherapy, 7 subsequently experienced leukemia relapse. In patients undergoing A-BMT, molecular fingerprinting of the TCR-Vβ repertoire, performed on antileukemia lines, demonstrated that selected antileukemia T-cell clonotypes, detectable in bone marrow before transplantation, survived ex vivo pharmacologic purging and were found in the recipient after A-BMT. These data provide evidence for an active role of autologous T cells in the maintenance of hematologic remission and also suggest that quantification of antileukemia CTLp frequency may be a useful tool to identify patients at high risk for relapse, thus potentially benefiting from an allogeneic antitumor effect.",
author = "Daniela Montagna and Rita Maccario and Franco Locatelli and Enrica Montini and Sara Pagani and Federico Bonetti and Liane Daudt and Ilaria Turin and Daniela Lisini and Claudio Garavaglia and Paolo Dellabona and Giulia Casorati",
year = "2006",
month = "12",
day = "1",
doi = "10.1182/blood-2006-05-021535",
language = "English",
volume = "108",
pages = "3843--3850",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia

AU - Montagna, Daniela

AU - Maccario, Rita

AU - Locatelli, Franco

AU - Montini, Enrica

AU - Pagani, Sara

AU - Bonetti, Federico

AU - Daudt, Liane

AU - Turin, Ilaria

AU - Lisini, Daniela

AU - Garavaglia, Claudio

AU - Dellabona, Paolo

AU - Casorati, Giulia

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Although the graft-versus-leukemia effect of allogeneic bone marrow transplantation (BMT) is of paramount importance in the maintenance of disease remission, the role played by the autologous T-cell response in antitumor immune surveillance is less defined. We evaluated the emergence of antileukemia cytotoxic T-lymphocyte precursors (CTLp's) and the correlation of this phenomenon with maintenance of hematologic remission in 16 children with acute myeloid leukemia (AML), treated with either chemotherapy alone (5 patients) or with autologous BMT (A-BMT, 11 patients). Antileukemia CTLp's were detectable in 8 patients in remission after induction chemotherapy; none of them subsequently had a relapse. Of the 8 patients who did not show detectable CTLp frequency while in remission after induction chemotherapy, 7 subsequently experienced leukemia relapse. In patients undergoing A-BMT, molecular fingerprinting of the TCR-Vβ repertoire, performed on antileukemia lines, demonstrated that selected antileukemia T-cell clonotypes, detectable in bone marrow before transplantation, survived ex vivo pharmacologic purging and were found in the recipient after A-BMT. These data provide evidence for an active role of autologous T cells in the maintenance of hematologic remission and also suggest that quantification of antileukemia CTLp frequency may be a useful tool to identify patients at high risk for relapse, thus potentially benefiting from an allogeneic antitumor effect.

AB - Although the graft-versus-leukemia effect of allogeneic bone marrow transplantation (BMT) is of paramount importance in the maintenance of disease remission, the role played by the autologous T-cell response in antitumor immune surveillance is less defined. We evaluated the emergence of antileukemia cytotoxic T-lymphocyte precursors (CTLp's) and the correlation of this phenomenon with maintenance of hematologic remission in 16 children with acute myeloid leukemia (AML), treated with either chemotherapy alone (5 patients) or with autologous BMT (A-BMT, 11 patients). Antileukemia CTLp's were detectable in 8 patients in remission after induction chemotherapy; none of them subsequently had a relapse. Of the 8 patients who did not show detectable CTLp frequency while in remission after induction chemotherapy, 7 subsequently experienced leukemia relapse. In patients undergoing A-BMT, molecular fingerprinting of the TCR-Vβ repertoire, performed on antileukemia lines, demonstrated that selected antileukemia T-cell clonotypes, detectable in bone marrow before transplantation, survived ex vivo pharmacologic purging and were found in the recipient after A-BMT. These data provide evidence for an active role of autologous T cells in the maintenance of hematologic remission and also suggest that quantification of antileukemia CTLp frequency may be a useful tool to identify patients at high risk for relapse, thus potentially benefiting from an allogeneic antitumor effect.

UR - http://www.scopus.com/inward/record.url?scp=33845262483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845262483&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-05-021535

DO - 10.1182/blood-2006-05-021535

M3 - Article

C2 - 16868250

AN - SCOPUS:33845262483

VL - 108

SP - 3843

EP - 3850

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -